Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00883090 · ClinicalTrials.gov registry record · Phase 2
A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency
A Phase 2 study of Factor XIII Deficiency, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 6
- Study locations
NCT00883090: Completed Phase 2 study of Factor XIII Deficiency, sponsored by CSL Behring.
NCT00883090 is a Phase 2 study of Factor XIII Deficiency that has completed, run by CSL Behring. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00883090, a Phase 2 study of Factor XIII Deficiency, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 6
- Study locations
Study Summary
Congenital deficiency of Factor XIII is an extremely rare hereditary disorder associated with potentially life-threatening bleeding. This study will evaluate the safety and recommended (best) amount or level of Factor XIII in a patient's blood. Factor XIII Concentrate (Human) is given to people whose blood is lacking Factor XIII. Factor XIII Concentrate (Human) works by assisting your blood in the usual clotting process, thereby preventing bleeding.
Conditions Studied
Interventions
- BIOLOGICAL FXIII Concentrate (Human)
Study Locations (6)
California
- Study Site - Orange
- Study Site - San Francisco
- Study Site - Stockton
Alabama
- Study Site - Dothan
Massachusetts
- Study Site - Boston
Other
- Study Site - Santa Cruz de Tenerife
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
What the finished NCT00883090 record still lists
NCT00883090 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Factor XIII Deficiency appearing as the primary indexed condition, and to 1 intervention - of which FXIII Concentrate (Human) is the first listed.
NCT00883090 lists 6 locations in 4 states (California, Alabama, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00883090 about?
NCT00883090 is a clinical study titled "A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency". Congenital deficiency of Factor XIII is an extremely rare hereditary disorder associated with potentially life-threatening bleeding. This study will evaluate the safety and recommended (best) amount or level of Factor XIII in a patient's blood. Factor XIII Concentrate (Human) is given to people whos...
What is the current status of trial NCT00883090?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2009-05. Estimated completion is 2010-04.
What conditions does trial NCT00883090 study?
This clinical trial studies the following conditions: Factor XIII Deficiency.
What interventions are being tested in trial NCT00883090?
The interventions under investigation include: FXIII Concentrate (Human) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00883090?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00883090 being conducted?
This trial has 6 study locations across Alabama, California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Factor XIII Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00883090's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia